Translating a world leading platform technology into commercialized precision medicine tests
OBD, now a public AIM-listed company with global reach, was spun out from Oxford University in 2007 with the aim of translating fundamental scientific advances in 3D Genomics into a new generation of commercialized blood tests for life-changing diseases, including delivering both EpiSwitch CiRT and EpiSwitch CST into the hands of doctors.